Cargando…
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366133/ https://www.ncbi.nlm.nih.gov/pubmed/37488099 http://dx.doi.org/10.1038/s41523-023-00567-6 |
| _version_ | 1785077103967862784 |
|---|---|
| author | Yang, Yang He, Yingjian Fan, Zhaoqing Chen, Xue Liu, Yiqiang Zhang, Chao Jiang, Hongchuan Wang, Xin Wang, Xiang Xie, Fei Wang, Shu Luo, Bin Kang, Hua Wang, Tao Jiang, Zefei Yuan, Peng Xu, Binhe Xu, Ling Liu, Yinhua Li, Jinfeng Xie, Yuntao Wang, Tianfeng Ouyang, Tao |
| author_facet | Yang, Yang He, Yingjian Fan, Zhaoqing Chen, Xue Liu, Yiqiang Zhang, Chao Jiang, Hongchuan Wang, Xin Wang, Xiang Xie, Fei Wang, Shu Luo, Bin Kang, Hua Wang, Tao Jiang, Zefei Yuan, Peng Xu, Binhe Xu, Ling Liu, Yinhua Li, Jinfeng Xie, Yuntao Wang, Tianfeng Ouyang, Tao |
| author_sort | Yang, Yang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10366133 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103661332023-07-26 Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial Yang, Yang He, Yingjian Fan, Zhaoqing Chen, Xue Liu, Yiqiang Zhang, Chao Jiang, Hongchuan Wang, Xin Wang, Xiang Xie, Fei Wang, Shu Luo, Bin Kang, Hua Wang, Tao Jiang, Zefei Yuan, Peng Xu, Binhe Xu, Ling Liu, Yinhua Li, Jinfeng Xie, Yuntao Wang, Tianfeng Ouyang, Tao NPJ Breast Cancer Author Correction Nature Publishing Group UK 2023-07-24 /pmc/articles/PMC10366133/ /pubmed/37488099 http://dx.doi.org/10.1038/s41523-023-00567-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Yang, Yang He, Yingjian Fan, Zhaoqing Chen, Xue Liu, Yiqiang Zhang, Chao Jiang, Hongchuan Wang, Xin Wang, Xiang Xie, Fei Wang, Shu Luo, Bin Kang, Hua Wang, Tao Jiang, Zefei Yuan, Peng Xu, Binhe Xu, Ling Liu, Yinhua Li, Jinfeng Xie, Yuntao Wang, Tianfeng Ouyang, Tao Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial |
| title | Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial |
| title_full | Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial |
| title_fullStr | Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial |
| title_full_unstemmed | Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial |
| title_short | Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial |
| title_sort | author correction: phase iii study of hr-positive/her2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366133/ https://www.ncbi.nlm.nih.gov/pubmed/37488099 http://dx.doi.org/10.1038/s41523-023-00567-6 |
| work_keys_str_mv | AT yangyang authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT heyingjian authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT fanzhaoqing authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT chenxue authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT liuyiqiang authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT zhangchao authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT jianghongchuan authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT wangxin authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT wangxiang authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT xiefei authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT wangshu authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT luobin authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT kanghua authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT wangtao authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT jiangzefei authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT yuanpeng authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT xubinhe authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT xuling authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT liuyinhua authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT lijinfeng authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT xieyuntao authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT wangtianfeng authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial AT ouyangtao authorcorrectionphaseiiistudyofhrpositiveher2negativelymphnodepositivebreastcancernonresponsivetoprimarychemotherapyarandomizedtrial |